|
1
|
Shrestha B, Haylor J and Raftery A:
Historical perspectives in kidney transplantation: an updated
review. Prog Transplant. 25:64–69. 762015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Newell KA: Clinical transplantation
tolerance. Semin Immunopathol. 33:91–104. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thorp EB, Stehlik C and Ansari MJ: T-cell
exhaustion in allograft rejection and tolerance. Curr Opin Organ
Transplant. 20:37–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waldmann H, Hilbrands R, Howie D and
Cobbold S: Harnessing FOXP3+ regulatory T cells for
transplantation tolerance. J Clin Invest. 124:1439–1445. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kinnear G, Jones ND and Wood KJ:
Costimulation blockade: current perspectives and implications for
therapy. Transplantation. 95:527–535. 2013. View Article : Google Scholar :
|
|
6
|
Kaur D and Brightling C: OX40/OX40 ligand
interactions in T-cell regulation and asthma. Chest. 141:494–499.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jensen SM, Maston LD, Gough MJ, Ruby CE,
Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, et
al: Signaling through OX40 enhances antitumor immunity. Semin
Oncol. 37:524–532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kotani A, Hori T, Fujita T, Kambe N,
Matsumura Y, Ishikawa T, Miyachi Y, Nagai K, Tanaka Y and Uchiyama
T: Involvement of OX40 ligand+ mast cells in chronic
GVHD after allogeneic hematopoietic stem cell transplantation. Bone
Marrow Transplant. 39:373–375. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou YB, Ye RG, Li YJ and Xie CM:
Targeting the CD134−CD134L interaction using anti-CD134
and/or rhCD134 fusion protein as a possible strategy to prevent
lupus nephritis. Rheumatol Int. 29:417–425. 2009. View Article : Google Scholar
|
|
10
|
Wang YL, Li G, Fu YX, Wang H and Shen ZY:
Blockade of OX40/OX40 ligand to decrease cytokine messenger RNA
expression in acute renal allograft rejection in vitro. Transplant
Proc. 45:2565–2568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Casiraghi F, Remuzzi G and Perico N:
Mesenchymal stromal cells to promote kidney transplantation
tolerance. Curr Opin Organ Transplant. 19:47–53. 2014. View Article : Google Scholar
|
|
12
|
Marx C, Silveira MD and Beyer Nardi N:
Adipose-derived stem cells in veterinary medicine: characterization
and therapeutic applications. Stem Cells Dev. 24:803–813. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alipour F, Parham A, Kazemi Mehrjerdi H
and Dehghani H: Equine adipose-derived mesenchymal stem cells:
phenotype and growth characteristics, gene expression profile and
differentiation potentials. Cell J. 16:456–465. 2015.PubMed/NCBI
|
|
14
|
Minteer DM, Marra KG and Rubin JP: Adipose
stem cells: biology, safety, regulation, and regenerative
potential. Clin Plast Surg. 42:169–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi T, Tibell A, Ljung K, Saito Y,
Gronlund A, Osterholm C, Holgersson J, Lundgren T, Ericzon BG,
Corbascio M, Kumagai-Braesch M, et al: Multipotent mesenchymal
stromal cells synergize with costimulation blockade in the
inhibition of immune responses and the induction of
Foxp3+ regulatory T cells. Stem Cells Transl Med.
3:1484–1494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clark JD, Gebhart GF, Gonder JC, Keeling
ME and Kohn DF: Special Report: the 1996 guide for the care and use
of laboratory animals. ILAR J. 38:41–48. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang YL, Li G, Zou XF, Chen XB, Liu T and
Shen ZY: Effect of autologous adipose-derived stem cells in renal
cold ischemia and reperfusion injury. Transplant Proc.
45:3198–3202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Redmond WL, Triplett T, Floyd K and
Weinberg AD: Dual anti-OX40/IL-2 therapy augments tumor
immunotherapy via IL-2R-mediated regulation of OX40 expression.
PLoS One. 7:e344672012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seifert M, Stolk M, Polenz D and Volk HD:
Detrimental effects of rat mesenchymal stromal cell pre-treatment
in a model of acute kidney rejection. Front Immunol. 3:2022012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu H, Ye Z and Mahato RI: Genetically
modified mesenchymal stem cells for improved islet transplantation.
Mol Pharm. 8:1458–1470. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Ezzelarab MB, Ayares D and Cooper
DK: The potential role of genetically-modified pig mesenchymal
stromal cells in xenotransplantation. Stem Cell Rev. 10:79–85.
2014. View Article : Google Scholar :
|
|
22
|
Stiehler M, Duch M, Mygind T, Li H,
Ulrich-Vinther M, Modin C, Baatrup A, Lind M, Pedersen FS and
Bünger CE: Optimizing viral and non-viral gene transfer methods for
genetic modification of porcine mesenchymal stem cells. Adv Exp Med
Biol. 585:31–48. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fülbier A, Schnabel R, Michael S, Vogt PM,
Strauß S, Reimers K and Radtke C: Successful nucleofection of rat
adipose-derived stroma cells with ambystoma mexicanum epidermal
lipoxygenase (AmbLOXe). Stem Cell Res Ther. 5:1132014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fakiruddin KS, Baharuddin P, Lim MN,
Fakharuzi NA, Yusof NA and Zakaria Z: Nucleofection optimization
and in vitro anti-tumourigenic effect of TRAIL-expressing human
adipose-derived mesenchymal stromal cells. Cancer Cell Int.
14:1222014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Copland IB, Qayed M, Garcia MA, Galipeau J
and Waller EK: Bone marrow mesenchymal stromal cells from patients
with acute and chronic graft-versus-host disease deploy normal
phenotype, differentiation plasticity, and immune-suppressive
activity. Biol Blood Marrow Transplant. 21:934–940. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Q, Qian S, Li J, Che N, Gu L, Wang Q,
Liu Y and Mei H: Combined transplantation of autologous
hematopoietic stem cells and allogenic mesenchymal stem cells
increases T regulatory cells in systemic lupus erythematosus with
refractory lupus nephritis and leukopenia. Lupus. 24:1221–1226.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Bari C: Are mesenchymal stem cells in
rheumatoid arthritis the good or bad guys? Arthritis Res Ther.
17:1132015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiao J, Yang R, Biswas S, Qin X, Zhang M
and Deng W: Mesenchymal stem cells and induced pluripotent stem
cells as therapies for multiple sclerosis. Int J Mol Sci.
16:9283–9302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kong D, Zhuang X, Wang D, Qu H, Jiang Y,
Li X, Wu W, Xiao J, Liu X, Liu J, et al: Umbilical cord mesenchymal
stem cell transfusion ameliorated hyperglycemia in patients with
type 2 diabetes mellitus. Clin Lab. 60:1969–1976. 2014.
|
|
30
|
Chullikana A, Majumdar AS, Gottipamula S,
Krishnamurthy S, Kumar AS, Prakash VS and Gupta PK: Randomized,
double-blind, phase I/II study of intravenous allogeneic
mesenchymal stromal cells in acute myocardial infarction.
Cytotherapy. 17:250–261. 2015. View Article : Google Scholar
|
|
31
|
Suksuphew S and Noisa P: Neural stem cells
could serve as a therapeutic material for age-related
neurodegenerative diseases. World J Stem Cells. 7:502–511. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lim MH, Ong WK and Sugii S: The current
landscape of adipose-derived stem cells in clinical applications.
Expert Rev Mol Med. 16:e82014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perico N, Casiraghi F, Introna M, Gotti E,
Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo
P, et al: Autologous mesenchymal stromal cells and kidney
transplantation: a pilot study of safety and clinical feasibility.
Clin J Am Soc Nephrol. 6:412–422. 2011. View Article : Google Scholar :
|
|
34
|
Perico N, Casiraghi F, Gotti E, Introna M,
Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo
P, et al: Mesenchymal stromal cells and kidney transplantation:
pretransplant infusion protects from graft dysfunction while
fostering immunoregulation. Transpl Int. 26:867–878. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W,
Li X, Chen Z, Ma J, Liao D, et al: Donor-derived mesenchymal stem
cells combined with low-dose tacrolimus prevent acute rejection
after renal transplantation: a clinical pilot study.
Transplantation. 95:161–168. 2013. View Article : Google Scholar
|
|
36
|
Reinders ME, de Fijter JW, Roelofs H,
Bajema IM, de Vries DK, Schaapherder AF, Claas FH, van Miert PP,
Roelen DL, van Kooten C, et al: Autologous bone marrow-derived
mesenchymal stromal cells for the treatment of allograft rejection
after renal transplantation: results of a phase I study. Stem Cells
Transl Med. 2:107–111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tan J, Wu W, Xu X, Liao L, Zheng F,
Messinger S, Sun X, Chen J, Yang S, Cai J, et al: Induction therapy
with autologous mesenchymal stem cells in living-related kidney
transplants: a randomized controlled trial. JAMA. 307:1169–1177.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Casiraghi F, Azzollini N, Todeschini M,
Cavinato RA, Cassis P, Solini S, Rota C, Morigi M, Introna M,
Maranta R, et al: Localization of mesenchymal stromal cells
dictates their immune or proinflammatory effects in kidney
transplantation. Am J Transplant. 12:2373–2383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Inoue S, Popp FC, Koehl GE, Piso P,
Schlitt HJ, Geissler EK and Dahlke MH: Immunomodulatory effects of
mesenchymal stem cells in a rat organ transplant model.
Transplantation. 81:1589–1595. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Popp FC, Eggenhofer E, Renner P, Slowik P,
Lang SA, Kaspar H, Geissler EK, Piso P, Schlitt HJ and Dahlke MH:
Mesenchymal stem cells can induce long-term acceptance of solid
organ allografts in synergy with low-dose mycophenolate. Transpl
Immunol. 20:55–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kato T, Okumi M, Tanemura M, Yazawa K,
Kakuta Y, Yamanaka K, Tsutahara K, Doki Y, Mori M, Takahara S and
Nonomura N: Adipose tissue-derived stem cells suppress acute
cellular rejection by TSG-6 and CD44 interaction in rat kidney
transplantation. Transplantation. 98:277–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang D, Wang LP, Zhou H, Cheng H, Bao XC,
Xu S, Zhang WP and Wang JM: Inducible costimulator gene-transduced
bone marrow-derived mesenchymal stem cells attenuate the severity
of acute graft-versus-host disease in mouse models. Cell
Transplant. 24:1717–31. 2015. View Article : Google Scholar
|
|
43
|
Wang YL, Tang ZQ, Gao W, Jiang Y, Zhang XH
and Peng L: Influence of Th1, Th2, and Th3 cytokines during the
early phase after liver transplantation. Transplant Proc.
35:3024–3025. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee JH, Jeon EJ, Kim N, Nam YS, Im KI, Lim
JY, Kim EJ, Cho ML, Han KT and Cho SG: The synergistic
immunoregulatory effects of culture-expanded mesenchymal stromal
cells and CD4(+)25(+)Foxp3+ regulatory T cells on skin allograft
rejection. PLoS One. 8:e709682013. View Article : Google Scholar : PubMed/NCBI
|
